Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
暂无分享,去创建一个
A. Young | M. Thase | S. Stahl | C. Nemeroff | S. Kasper | R. McIntyre | P. Gorwood | M. Berk | E. Vieta | J. Rosenblat | J. G. Lee | E. Brietzke | R. Ho | R. Mansur | G. Sanacora | D. Iosifescu | G. Papakostas | S. Dodd | J. Murrough | Yena Lee | Mehala Subramaniapillai | C. L. López Jaramillo | C. Zarate | L. Lui | Kevin Kratiuk
[1] Nelson B Rodrigues,et al. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment , 2021, Psychopharmacology.
[2] Nelson B Rodrigues,et al. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. , 2021, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[3] Nelson B Rodrigues,et al. The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research , 2020, Neuroscience & Biobehavioral Reviews.
[4] J. Moncrieff,et al. Are we repeating mistakes of the past? A review of the evidence for esketamine , 2020, The British Journal of Psychiatry.
[5] Nelson B Rodrigues,et al. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. , 2020, Journal of psychiatric research.
[6] Nelson B Rodrigues,et al. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation , 2020, CNS Spectrums.
[7] Nelson B Rodrigues,et al. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence , 2020, CNS Spectrums.
[8] C. Zarate,et al. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. , 2020, Journal of affective disorders.
[9] Nelson B Rodrigues,et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. , 2020, Journal of affective disorders.
[10] W. Drevets,et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) , 2020, The international journal of neuropsychopharmacology.
[11] J. Kane,et al. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System , 2020, Psychotherapy and Psychosomatics.
[12] S. Chakravarty,et al. Rapid acting antidepressants in the mTOR pathway: Current evidence , 2020, Brain Research Bulletin.
[13] R. McIntyre,et al. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. , 2020, Journal of affective disorders.
[14] W. Drevets,et al. Genome-wide association study and polygenic risk score analysis of esketamine treatment response , 2020, Scientific Reports.
[15] M. Bauer,et al. Urothelial toxicity of esketamine in the treatment of depression , 2020, Psychopharmacology.
[16] J. Swainson,et al. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises. , 2020, Journal of clinical psychopharmacology.
[17] D. Soeteman,et al. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. , 2020, Psychiatric services.
[18] Jun Liu,et al. Opioid Receptor μ-1 and Ketamine Effects in a Suicidal Depression Trial: A Post Hoc Exploration. , 2020, Journal of clinical psychopharmacology.
[19] L. Bartova,et al. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment , 2020, The international journal of neuropsychopharmacology.
[20] E. Ballard,et al. Neurobiological biomarkers of response to ketamine. , 2020, Advances in pharmacology.
[21] Nelson B Rodrigues,et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence , 2020, Expert opinion on drug safety.
[22] A. Young,et al. Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis , 2020, International review of psychiatry.
[23] S. Kennedy,et al. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol , 2020, BMC Psychiatry.
[24] L. Jerome,et al. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments , 2020, Expert review of clinical pharmacology.
[25] M. Fava,et al. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. , 2020, The Journal of clinical psychiatry.
[26] Nelson B Rodrigues,et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder , 2020, Bipolar disorders.
[27] Xiang Li,et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). , 2020, The Journal of clinical psychiatry.
[28] M. Fava,et al. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder , 2020, Journal of clinical psychopharmacology.
[29] A. Young,et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). , 2020, The Journal of clinical psychiatry.
[30] A. Rush,et al. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. , 2020, Journal of affective disorders.
[31] A. Serretti,et al. New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. , 2020, Medicinal research reviews.
[32] S. Southwick,et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin , 2020, Neuropsychopharmacology.
[33] G. Papakostas. Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. , 2020, The Journal of clinical psychiatry.
[34] Jaskaran Singh,et al. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program , 2020, CNS Drugs.
[35] C. Zarate,et al. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation , 2020, Pharmacology Biochemistry and Behavior.
[36] R. Malinow,et al. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents , 2020, Proceedings of the National Academy of Sciences.
[37] Jie Luo,et al. Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy. , 2020, The journal of ECT.
[38] E. Stern,et al. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression , 2020, Neuropsychopharmacology.
[39] W. Drevets,et al. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. , 2020, Advances in pharmacology.
[40] M. Fava,et al. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. , 2020, Journal of affective disorders.
[41] M. Pavlicova,et al. A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. , 2019, The American journal of psychiatry.
[42] J. Talbot,et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression , 2019, Neuropsychopharmacology.
[43] R. Shelton,et al. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial , 2019, Depression and anxiety.
[44] C. Loo,et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials , 2019, The Australian and New Zealand journal of psychiatry.
[45] E. Vieta. Disruptive treatments in psychiatry. , 2019 .
[46] Cynthia J. Stoppel,et al. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. , 2019, The Journal of clinical psychiatry.
[47] E. Turner,et al. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. , 2019, The lancet. Psychiatry.
[48] W. Drevets,et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[49] A. Schatzberg. More Thoughts on Intranasal Esketamine: Response to Drevets et al. , 2019, The American journal of psychiatry.
[50] A. Włodarczyk,et al. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. , 2019, Psychiatria Danubina.
[51] Xiang Li,et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.
[52] D. M. Lyons,et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism , 2019, Molecular Psychiatry.
[53] Keith Cheng,et al. Successful Use of Ketamine for the Treatment of Psychotic Depression in a Teenager. , 2019, Journal of child and adolescent psychopharmacology.
[54] S. Dursun,et al. Esketamine for treatment-resistant depression , 2020, Drug and Therapeutics Bulletin.
[55] M. Fava,et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) , 2019, The international journal of neuropsychopharmacology.
[56] M. Pavlicova,et al. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. , 2019, The American journal of psychiatry.
[57] A. Schatzberg,et al. Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. , 2019, JAMA psychiatry.
[58] R. Shelton,et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.
[59] R. McIntyre,et al. Oral Ketamine for Depression: A Systematic Review. , 2019, The Journal of clinical psychiatry.
[60] G. Kheirabadi,et al. Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial , 2019, Advanced biomedical research.
[61] C. Andrade. Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence. , 2019, The Journal of clinical psychiatry.
[62] D. Charney,et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial , 2019, Neuropsychopharmacology.
[63] J. Krystal,et al. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder , 2019, JAMA psychiatry.
[64] J. Kehr,et al. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function , 2019, Proceedings of the National Academy of Sciences.
[65] M. Shao,et al. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. , 2019, Contemporary clinical trials.
[66] David Benrimoh,et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. , 2019, Journal of affective disorders.
[67] Young T. Hong,et al. Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex , 2019, Neuron.
[68] M. Fava,et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression , 2018, Depression and anxiety.
[69] H. Loshak,et al. Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines , 2019 .
[70] B. Vrooman,et al. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization , 2018, Medical sciences.
[71] M. Thase,et al. Improving Depression Outcome by Patient-Centered Medical Management. , 2018, The American journal of psychiatry.
[72] M. Fava,et al. Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depres , 2019 .
[73] M. George. Is There Really Nothing New Under the Sun? Is Low-Dose Ketamine a Fast-Acting Antidepressant Simply Because It Is An Opioid? , 2018, The American journal of psychiatry.
[74] D. M. Lyons,et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. , 2018, The American journal of psychiatry.
[75] H. Ruhé,et al. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression , 2018, Psychological Medicine.
[76] L. Bartova,et al. Rapid antidepressant effect of S-ketamine in schizophrenia , 2018, European Neuropsychopharmacology.
[77] W. McDonald,et al. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. , 2018, Journal of affective disorders.
[78] D. Kahn,et al. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior , 2018, Journal of psychiatric practice.
[79] T. Gould,et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms , 2018, Pharmacological Reviews.
[80] S. Dravid,et al. Region-specific Expression of NMDA Receptor GluN2C Subunit in Parvalbumin-Positive Neurons and Astrocytes: Analysis of GluN2C Expression using a Novel Reporter Model , 2018, Neuroscience.
[81] S. Wilkinson,et al. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor. , 2018, General hospital psychiatry.
[82] Tyrone D. Cannon,et al. Can a Framework Be Established for the Safe Use of Ketamine? , 2018, The American journal of psychiatry.
[83] W. Drevets,et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. , 2018, The American journal of psychiatry.
[84] R. McIntyre,et al. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder , 2018, International journal of environmental research and public health.
[85] T. Gould,et al. Mechanisms of ketamine action as an antidepressant , 2018, Molecular Psychiatry.
[86] L. Marshall,et al. Bipolar disorders , 2018, Nature Reviews Disease Primers.
[87] E. Ballard,et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. , 2018, Journal of affective disorders.
[88] A. Lacerda,et al. Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series , 2018, Biological Psychiatry.
[89] E. Ballard,et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.
[90] W. Drevets,et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study , 2016, Psychopharmacology.
[91] C. Loo,et al. Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.
[92] M. Thase. New medications for treatment-resistant depression: a brief review of recent developments , 2017, CNS Spectrums.
[93] C. Andrade. Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions. , 2017, The Journal of clinical psychiatry.
[94] E. Ballard,et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. , 2017, Journal of affective disorders.
[95] S. Wilkinson,et al. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. , 2017, The American journal of psychiatry.
[96] T. Kircher,et al. S-ketamine compared to etomidate during electroconvulsive therapy in major depression , 2017, European Archives of Psychiatry and Clinical Neuroscience.
[97] M. Frye,et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.
[98] Kathryn R. Cullen,et al. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use. , 2017, The Journal of clinical psychiatry.
[99] W. Meng,et al. Drugs of abuse and their metabolites in the urban rivers of Beijing, China: Occurrence, distribution, and potential environmental risk. , 2017, The Science of the total environment.
[100] D. Luckenbaugh,et al. Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion , 2017, Biological Psychiatry.
[101] Trina E. Chang,et al. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation , 2017, The Australian and New Zealand journal of psychiatry.
[102] P. Mitchell,et al. Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression , 2016, Acta psychiatrica Scandinavica.
[103] Xi-Ping Huang,et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.
[104] R. Shelton,et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.
[105] G. Aghajanian,et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants , 2016, Nature Medicine.
[106] Keith M. Harris,et al. Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications , 2016, BMC Medical Ethics.
[107] I. Dhalla,et al. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2016, Ontario health technology assessment series.
[108] R. McIntyre,et al. Treating to target in major depressive disorder: response to remission to functional recovery , 2015, CNS Spectrums.
[109] Y. Hsu,et al. Possible pathophysiology of ketamine‐related cystitis and associated treatment strategies , 2015, International journal of urology : official journal of the Japanese Urological Association.
[110] W. Goodman,et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial , 2015, Psychological Medicine.
[111] C. Galletly,et al. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression , 2015, The Australian and New Zealand journal of psychiatry.
[112] M. Frye,et al. Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development , 2015, Journal of clinical psychopharmacology.
[113] Meiling Zhang,et al. Assessment of the effect of ketamine on cytochrome P450 isoforms activity in rats by cocktail method. , 2015, International journal of clinical and experimental medicine.
[114] D. Charney,et al. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial , 2015, Neuropsychopharmacology.
[115] A. Schatzberg,et al. Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? , 2015, Neuropsychopharmacology.
[116] K. Kucia,et al. The use of ketamine in electroconvulsive therapy. , 2015, Psychiatria polska.
[117] Helen S. Mayberg,et al. Neuroimaging-based biomarkers for treatment selection in major depressive disorder , 2014, Dialogues in clinical neuroscience.
[118] Michael K Parides,et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. , 2014, JAMA psychiatry.
[119] D. Luckenbaugh,et al. Clinical predictors of ketamine response in treatment-resistant major depression. , 2014, The Journal of clinical psychiatry.
[120] D. Luckenbaugh,et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? , 2014, Journal of affective disorders.
[121] A. Schatzberg. A word to the wise about ketamine. , 2014, The American journal of psychiatry.
[122] Benjamin S. Glicksberg,et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response , 2013, Psychopharmacology.
[123] Dennis S. Charney,et al. Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.
[124] Q. Guo,et al. Genitourinary toxicity of ketamine. , 2013, Hong Kong medical journal = Xianggang yi xue za zhi.
[125] Paul Kudlow,et al. COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS , 2013, Depression and anxiety.
[126] D. Gillatt,et al. The prevalence and natural history of urinary symptoms among recreational ketamine users , 2012, BJU international.
[127] G. Aghajanian,et al. Synaptic Dysfunction in Depression: Potential Therapeutic Targets , 2012, Science.
[128] D. Luckenbaugh,et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. , 2012, British journal of clinical pharmacology.
[129] D. Luckenbaugh,et al. Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study , 2012, Neuropsychopharmacology.
[130] E. Berrocoso,et al. The Mu-Opioid Receptor and the NMDA Receptor Associate in PAG Neurons: Implications in Pain Control , 2012, Neuropsychopharmacology.
[131] D. Luckenbaugh,et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.
[132] D. Charney,et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. , 2010, The international journal of neuropsychopharmacology.
[133] Leslie Muetzelfeldt,et al. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. , 2010, Addiction.
[134] H. Möller,et al. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? , 2009, International clinical psychopharmacology.
[135] Guang Chen,et al. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.
[136] C. Morgan,et al. Attentional bias to incentive stimuli in frequent ketamine users , 2008, Psychological Medicine.
[137] M. Narita,et al. Post‐synaptic action of morphine on glutamatergic neuronal transmission related to the descending antinociceptive pathway in the rat thalamus , 2007, Journal of neurochemistry.
[138] C. Streutker,et al. Ketamine-associated ulcerative cystitis: a new clinical entity. , 2004, Urology.
[139] C. Morgan,et al. Acute and chronic effects of ketamine upon human memory: a review , 2006, Psychopharmacology.
[140] C. Morgan,et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose–response study , 2003, Psychopharmacology.
[141] J. Krystal,et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. , 2000, Archives of general psychiatry.
[142] S. Fortuna,et al. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. , 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[143] Anil K Malhotra,et al. Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.
[144] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[145] F. Vollenweider,et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) , 1997, European Neuropsychopharmacology.